generated using the Antechamber module in Amber. All atom versions of the Amber03 force field (ff03) [2] and the general Amber force field (GAFF) [3] were used for the protein and the inhibitors respectively. The Xleap module was used to prepare the system for the MD simulations. All the simulation systems were neutralized with appropriate numbers of counter ions. Each neutralized system was solvated in an octahedral box with TIP3P [4] water molecules, leaving at least 10Å between the solute atoms and the borders of the box.
All MD simulations were carried out in explicit solvent at 300K. During the simulations, the long-range electrostatic interactions were treated with the particle mesh Ewald [5] method using a real space cut off distance of 9Å. The Settle [6] algorithm was used to constrain bond vibrations involving hydrogen atoms, which allowed a time step of 2fs during the simulations.
The models of the complexes of EAI045 (with EGFR L858R and EGFR L861Q ) were generated as follows: MD simulations of the apo forms of EGFR L858R and EGFR L861Q were carried out and the sampled conformations were subject to RMSD-based clustering. Representatives of the top 10 clusters of each protein were then taken and EAI045 was docked to each chosen conformation. From these docked complexes, we chose a model from the EAI045 -EGFR L858R states and a model from the EAI045 -EGFR L861Q states in which the bound EAI045 adopted a conformation similar (closest rmsd was ~0.8 Å) to its binding mode seen in the published co-crystal structure of EAI001 complexed with the EGFR T790M/V948R (PDB code 5d41) and subsequently subjected these two chosen models to MD simulations.
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For each system, the solvent molecules and counter ions were initially relaxed using energy minimization with restraints on the protein and inhibitor atoms. This was followed by unrestrained energy minimization to remove any steric clashes. Subsequently the system was gradually heated from 0 to 300 K using MD simulations with positional restraints (force constant: 50 kcal mol -1 Å -2 ) on protein and inhibitor atoms over a period of 0.25 ns allowing water molecules and ions to move freely. During an additional 0.25 ns, the positional restraints were gradually reduced followed by a 2 ns unrestrained MD simulation to equilibrate all the atoms. Finally, each system was subject to production simulations and the details are listed in Table S2 .
Analysis of the MD simulations was carried out by examining several properties. Root mean square deviation (RMSD) of the sampled conformations against the starting structure and average atomic fluctuations (Root mean square fluctuations or RMSF) over all sampled conformations during the stable parts of the production phases of the MD simulations were calculated using the ptraj module in Amber. Solvent Accessible Surface Area (SASA) was computed using NACCESS [7] . Volume of the allosteric pocket was calculated using the trj_cavity program [8] . Evolution of the secondary structures was calculated using the dssp program [9] . In the case of EGFR WT (inactive), EGFR L858R (inactive), EGFR T790M (inactive) EGFR L858R/T790M and EGFR L861Q , analysis was carried out over the 1 µs simulation trajectory, for the other systems, either the 100ns or the 250ns production simulations were used. Three parameters: 1. backbone dihedrals of residues that form the short α-helix; 2. volume of the allosteric pocket; 3. rmsd of the short α-helix), were used for constructing the Free Energy Surfaces (FES). The backbone dihedrals values were calculated for each of the 7 amino acids that make up the short α-helix and averaged for each conformation sampled during the 1 µs MD simulations. RMSD (with respect to the starting folded α-helical conformation) of 4 residues from 857 to 863 that form the short α-helix was calculated for all the conformations sampled during the 1 µs MD simulations. The allosteric pocket was defined by residues that are within 6 Å of the EAI045 inhibitor binding site in the crystal structure 5D41.pdb and the volume of the pocket was calculated using the program trj_cavity [8] from the conformations sampled during the 1 µs MD simulations of the respective systems. Simulation trajectories were visualized using VMD [10] and figures were generated using PyMOL [11] .
Energy Calculations
The binding free energies of complexes EAI045 -EGFR L858R and EAI045 -EGFR L861Q were calculated using the MMPBSA (Molecular Mechanics Poisson-Boltzmann Surface Area) methodology [12] implemented in AMBER 14 [1] . 250 conformations from the last 500 ns of the MD simulations of each EAI045 -EGFR L858R and EAI045 -EGFR L861Q complex were taken and water molecules and counterions removed. Binding free energies (ΔG bind ) were calculated for each conformation using:
where
ΔG MM is the change in the molecular mechanics energy upon complexation in the gas phase, ΔG sol is the change in solvation free energy and TΔS is the change of conformational entropy associated with ligand binding. The molecular mechanics free energy (ΔG MM ) is further split into Van der Waals (ΔG vdw ) and electrostatic (ΔG ele ) energies:
The solvation free energy ΔG sol arises from polar (electrostatic) solvation free energy (ΔG PB ) and nonpolar solvation free energy (ΔG SA ) as in eq 4:
ΔG PB is computed by solving the linearized Poisson -Boltzmann (PB) equation using Parse radii and a solvent probe radius of 1.4 Ǻ. In these calculations, the dielectric constant was set to 1.0 for the interior of the solutes and 80.0 for the solvent. ΔG SA was determined using a solvent accessible surface area (SASA)-dependent term as in eq 5:
where γ is the surface tension proportionality constant and was set to 0.00542 kcal/(mol·Å −2 ), and β is the offset value, which was 0.92 kcal/mol here.
The entropy term (−TΔS) was not computed, therefore the binding free energy calculated here corresponds to only the enthalpic contribution.
Experimental Methods
In vitro binding assay was performed using KINOMEscan TM at the company DiscoverX. 
